In Fig. 1a, the SGO2 mRNA expression level was significantly higher in the WHO grade IV (n = 81) than in grade III gliomas (n = 19; p = 7.77 × 10–4), grade II gliomas (n = 7; p = 8.67 × 10−11), and in non-tumor controls (n = 23; p = 5.81 × 10−20). This evidence concerns the gene SGO2 and central nervous system cancer.